Tyrosine Kinase/Adaptateurs
Les inhibiteurs des tyrosines kinases et des adaptateurs sont des composés qui ciblent les tyrosines kinases et leurs protéines adaptatrices associées, jouant des rôles essentiels dans la signalisation cellulaire, la croissance et la différenciation. Ces inhibiteurs sont des outils essentiels dans la recherche sur le cancer, car de nombreuses tyrosines kinases sont impliquées dans les voies de signalisation qui favorisent la croissance tumorale et les métastases. En inhibant les tyrosines kinases, ces composés peuvent bloquer des cascades de signalisation cruciales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies impliquant une signalisation cellulaire anormale. Chez CymitQuimica, nous offrons une gamme complète d'inhibiteurs de tyrosines kinases et d'adaptateurs de haute qualité pour soutenir vos recherches en oncologie, biologie moléculaire et développement de thérapies ciblées.
Sous-catégories appartenant à la catégorie "Tyrosine Kinase/Adaptateurs"
- ALK(112 produits)
- CSF-1R(42 produits)
- EGFR(572 produits)
- Récepteur Ephrin(23 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- SON(5 produits)
- Hck(3 produits)
- IGF-1R(86 produits)
- PDGFR(126 produits)
- PYK2(7 produits)
- Src(78 produits)
- Récepteur TAM(32 produits)
- Tie-2(20 produits)
- Récepteur Trk(59 produits)
- Tyrosine Kinases(27 produits)
- VEGFR(268 produits)
- c-Fms(108 produits)
- c-Kit(101 produits)
- c-Met/HGFR(128 produits)
- c-RET(51 produits)
Affichez 13 plus de sous-catégories
1375 produits trouvés pour "Tyrosine Kinase/Adaptateurs"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
FMP-API-1
CAS :<p>FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).</p>Formule :C13H14N2O2Couleur et forme :SolidMasse moléculaire :230.262GENZ-882706
CAS :<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>Formule :C26H25N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :455.51TRK-IN-26
CAS :<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Formule :C30H22F2N6O4Couleur et forme :SolidMasse moléculaire :568.53EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45TrkC-IN-1
CAS :<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Formule :C28H20BrN5O2Couleur et forme :SolidMasse moléculaire :538.395FGFR4-IN-4
CAS :<p>FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.</p>Formule :C28H32Cl2N6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :603.5TRK-IN-28
CAS :<p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>Formule :C27H25F2N7Couleur et forme :SolidMasse moléculaire :485.53DDR1-IN-10
CAS :<p>DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.</p>Formule :C24H25F4N5O2Couleur et forme :SolidMasse moléculaire :491.481NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64TrkA-IN-7
CAS :<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Formule :C16H13N3O3Couleur et forme :SolidMasse moléculaire :295.293JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54Lucitanib dihydrochloride
CAS :<p>Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.</p>Formule :C26H27Cl2N3O4Couleur et forme :SolidMasse moléculaire :516.42PET-cGMP
CAS :<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Formule :C18H16N5O7PCouleur et forme :SolidMasse moléculaire :445.323HER2-IN-6
CAS :<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58AMG-25
CAS :<p>AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.</p>Formule :C23H17N5O2Degré de pureté :98.16%Couleur et forme :SolidMasse moléculaire :395.41HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424EGFR-IN-38
CAS :<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98Sacibertinib
CAS :<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08VEGFR2-IN-1
CAS :<p>VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.</p>Formule :C22H18N6SDegré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :398.48EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39Tesevatinib tosylate
CAS :<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59DDR1-IN-8
CAS :<p>DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.</p>Formule :C23H24F3N5O2Masse moléculaire :459.46HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23BNN-20
CAS :<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Formule :C20H30O2Couleur et forme :SolidMasse moléculaire :302.45EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formule :C12H14N4OS2Couleur et forme :SolidMasse moléculaire :294.4c-Fms-IN-15
CAS :<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>Formule :C29H28F3N7O2Masse moléculaire :563.57Protein kinase inhibitor 4
CAS :<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Formule :C25H24F2N6O3SMasse moléculaire :526.56BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formule :C24H15FO3Couleur et forme :SolidMasse moléculaire :370.37CL-A3-7
CAS :<p>CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.</p>Formule :C24H22Br2F2N2O3Couleur et forme :SolidMasse moléculaire :584.252-Methyl-3-phenylquinoxaline
CAS :<p>2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).</p>Formule :C15H12N2Couleur et forme :SolidMasse moléculaire :220.27EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33FGFR-IN-16
CAS :<p>FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.</p>Formule :C30H27Cl2N7O4Couleur et forme :SolidMasse moléculaire :620.49EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Couleur et forme :SolidG-744
CAS :<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Formule :C29H29N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :527.64TAS05567
CAS :<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Formule :C21H29N9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :439.51EGFR-IN-126
CAS :<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.278-Br-cGMP-AM
CAS :<p>8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.</p>Formule :C13H15BrN5O9PCouleur et forme :SolidMasse moléculaire :496.16DYRKs-IN-1
CAS :<p>DYRKs-IN-1 has antitumor activity.</p>Formule :C30H30ClN7O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :588.06BIIB129
CAS :<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Formule :C19H22N6O2Degré de pureté :98.56%Couleur et forme :SolidMasse moléculaire :366.42Vecabrutinib
CAS :<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Formule :C22H24ClF4N7O2Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :529.92Enbezotinib
CAS :<p>Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.</p>Formule :C21H21FN6O3Degré de pureté :99.84%Couleur et forme :SolidMasse moléculaire :424.43AZ12601011
CAS :<p>AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.</p>Formule :C19H15N5Degré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :313.36Zotizalkib
CAS :<p>TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.</p>Formule :C21H20F3N5O3Degré de pureté :98.7%Couleur et forme :SolidMasse moléculaire :447.41AGL-2263
CAS :<p>AGL-2263 is a blocker of insulin receptor (IR)</p>Formule :C17H10N2O5Couleur et forme :SolidMasse moléculaire :322.27EGFR-IN-7
CAS :<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formule :C32H41BrN9O2PDegré de pureté :95.32% - 99.64%Couleur et forme :SolidMasse moléculaire :694.6HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Couleur et forme :Odour LiquidNimotuzumab (powder)
CAS :<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Couleur et forme :LiquidTLC9995-0188
CAS :<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Formule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331Tyrosine kinase inhibitor
CAS :<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Formule :C31H31FN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :586.61Duligotuzumab
CAS :<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Degré de pureté :95%Couleur et forme :LiquidEGFR-IN-82
CAS :<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formule :C32H41BrN9O2PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :694.6FGFR1 inhibitor-10
CAS :<p>FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation.</p>Formule :C26H30F3N7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :561.62Trk-IN-4
CAS :<p>Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.</p>Formule :C24H23F4N5O4Degré de pureté :98.13%Couleur et forme :SolidMasse moléculaire :521.46YK-029A
CAS :<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formule :C27H32N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.6TrkB-IN-1
CAS :<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formule :C19H16N2O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :368.34JDB175
CAS :<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Formule :C26H21F3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.47Syk-IN-8
CAS :<p>Syk-IN-8 (compound 19q) functions as a Syk inhibitor with demonstrated antiproliferative effects on a variety of hematological tumor cells.</p>Formule :C23H26N10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.52BTK-IN-25
CAS :<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Formule :C28H27F2N3O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :523.53Canlitinib
CAS :<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formule :C33H31F2N3O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :619.61BTK-IN-27
CAS :<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Formule :C31H35N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :537.66APG-2449
CAS :<p>APG-2449 is an orally active inhibitor targeting ALK, ROS1, and FAK, demonstrating antitumor efficacy in mouse models of non-small cell lung cancer (NSCLC) [1].</p>Formule :C33H42ClN5O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :640.24EGFR-IN-123
CAS :<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formule :C24H27F3N6OCouleur et forme :SolidMasse moléculaire :472.51EGFR-IN-122
CAS :<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formule :C19H20N4O3Couleur et forme :SolidMasse moléculaire :352.39
